

Complementary therapy for the management of 'white coat hypertension syndrome' (a condition where a patient's blood pressure is higher when measured at a doctor's office than in other settings)

Submission date 21/08/2024	Recruitment status Recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 26/11/2024	Overall study status Ongoing	☐ Statistical analysis plan
		☐ Results
Last Edited 30/01/2026	Condition category Mental and Behavioural Disorders	☐ Individual participant data
		☒ Record updated in last year

Plain English summary of protocol

Background and study aims

This research will examine the impact of personalised complementary therapy for the management of generalised anxiety disorder (GAD) and white coat hypertension syndrome (WCHS) within early-phase oncology clinical trial patients and patients with advanced cancer.

Who can participate?

Adult patients with cancer referred for early-phase clinical trials. Cancer patients attending secondary care appointments, including secondary breast cancer patients and teenagers and young adults (16 to 24 Year olds).

What does the study involve?

In Arm 1, patients will be assessed by a trained complementary therapist to create a personalised treatment programme, which may include massage (hand and foot), aromatherapy, reflexology, Indian head massage, reiki, relaxation, visualisation, guided imagery, and mindfulness. If hypertension persists at study visits 3 and 4, participants will be reviewed by the medical and nursing team and may be transferred to standard care. Arm 2 participants will receive standard care only, involving a review by the nursing team, discussions about their well-being, repeated blood pressure checks, and if necessary, referral to the medical team for further evaluation and potential home blood pressure monitoring or medication.

What are the possible benefits and risks of participating?

This is the first study to look at using complementary therapy for WCHS and the findings from this research will show if complementary therapy is an effective treatment for white coat hypertension. The findings from this research may lead to a change in how WCHS is managed with the NHS; with the aim of improving patient's experiences of being on an early phase clinical trial.

Taking part may mean your appointment will last longer, and you may want to consider this when talking to the research nurse about this study.

Where is the study run from?

Newcastle upon Tyne Hospitals NHS Foundation Trust

When is the study starting and how long is it expected to run for?

July 2023 to January 2027

Who is funding the study?

Newcastle upon Tyne Hospitals NHS Foundation Trust

Who is the main contact?

Dr Ben Hood, ben.hood@nhs.net

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Ben Hood

ORCID ID

<https://orcid.org/0000-0003-1982-6745>

Contact details

Sir Bobby Robson Cancer Trials Research Centre

Freeman road

Newcastle upon Tyne

United Kingdom

NE22 6LJ

+44 (0)1912139217

ben.hood@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)

327774

Protocol serial number

Newcastle R & D number - 10527

Study information

Scientific Title

A randomised control trial, evaluating the effect of a personalised complementary therapy intervention for the management of white coat hypertension syndrome within early phase oncology clinical trial patients

Acronym

PRECISE

Study objectives

This research will examine the impact of a personalised complementary therapy intervention for the management of 'White Coat Hypertension' within early-phase oncology clinical trial patients. Cancer patients that take part in early-phase clinical trials have advanced cancer; a type of cancer that is terminal. In many cases these set of patients have exhausted all NHS treatment options available to them and are sometimes offered the opportunity to take part in an early phase clinical trial; to get access to an experimental cancer treatment.

Research shows that advanced cancer patients have a lot of anxiety, as a consequence of disease burden. Research also shows that advanced cancer patients anxiety levels increase when attending hospital appointments, in particular clinical trial appointments. Further research has also shown that increased anxiety levels make patients' blood pressure rise, when they are attending these type of appointments. This is often called white coat hypertension; which, if untreated increases patients risk of heart attack and stroke.

Personalised complementary therapy is used within the NHS to support cancer patients; making them feel more relaxed and reduce their anxiety levels. Within our clinical team we have witnessed at first hand the impact complementary therapy has, and believe it does have a positive impact on anxiety and white coat hypertension.

To date there has been no clinical research to examine if complementary therapy is an effective treatment for anxiety and white coat hypertension.

The primary objectives of this research are:

1. To investigate if personalised complementary therapy is an effective intervention in the management of anxiety and white coat hypertension
2. To investigate if personalised complementary therapy is more effective than current gold standard practices for the management of white coat hypertension
3. To investigate what the rates of white coat hypertension are amongst early-phase cancer clinical trial patients

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 14/08/2023, London - Riverside Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8023; riverside.rec@hra.nhs.uk), ref: 23/LO/0701

Primary study design

Interventional

Study design

Interventional randomized controlled trial

Study type(s)

Efficacy, Quality of life

Health condition(s) or problem(s) studied

White coat hypertension

Interventions

Patients will be randomised into two study arms using electronic Recap 1:1 randomisation. The interventions last 1 hour with no follow-up activities.

Arm 1

Patients randomised to arm 1; the complementary therapy arm, will be assessed by a trained complementary therapist, to create a personalised complementary therapy treatment programme. Participants will either receive massage, including hand and foot, aromatherapy, reflexology, Indian head massage, and reiki, or relaxation, visualisation, guided imagery and mindfulness.

In addition, if hypertension persists at study visits 3 and 4; arm 1 participants would be reviewed by the medical and nursing team and a decision would be made to transfer the participant to a standard of care.

Arm 2

Arm 2 participants will receive a standard of care only.

Standard of care - Review by the nursing team; discussion with patients around how they are feeling (BP repeated after discussion). At the next visit, if BP is still high, the patient is to be referred to the medical team. This would include a detailed medical history and physical exam; to examine possible causes of elevated BP, such as undiagnosed hypertension or drug-related. If no obvious cause is found, consider home BP monitoring (at least twice daily for 7 days). At the next appointment, if BP continued to be raised a medical decision would be made – either to medicate the patient with anti-hypertension medication, and/or refer the patient to their general practitioner.

Intervention Type

Behavioural

Primary outcome(s)

1. Blood pressure measured using a sphygmomanometer at pre and post-complementary therapy, and pre and post-standard-of-care visits
2. Anxiety measured using the Generalized Anxiety Disorder (GAD-7) scale at every visit, before any intervention of standard of care treatment for WCH or GAD

Key secondary outcome(s)

The rate of white coat hypertension syndrome measured using data collected in patient medical records at visit one and visit two, as part of screening

Completion date

01/01/2027

Eligibility

Key inclusion criteria

1. Men or women 16 years and above
2. Confirmed diagnosis of advanced cancer
3. Confirmed GAD-7 score of 10 or above and / or 1WCH (1 WCHA criteria: A discrepancy of more than 20/10 mmHg between clinic and median daytime BP (NICE, 2022))

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

16 Years

Upper age limit

80 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Previous confirmed diagnosis of hypertension
2. Unconfirmed WCH
3. Patients receiving a treatment with known cardio toxicity that effects BP

Date of first enrolment

14/10/2023

Date of final enrolment

01/01/2027

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

The Newcastle upon Tyne Hospitals NHS Foundation Trust

Freeman Hospital

Freeman Road

High Heaton

Newcastle upon Tyne

England

NE7 7DN

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust

ROR

<https://ror.org/05p40t847>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Newcastle upon Tyne Hospitals NHS Foundation Trust

Alternative Name(s)

Newcastle upon Tyne Hospitals NHS Trust

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication

IPD sharing plan summary

Published as a supplement to the results publication